2996 T3D2954 Frovatriptan Frovatriptan (Frova&#8482;) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1] Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets. Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans. Frovatriptan is available only by prescription in the United States, where a secondary New Drug Approval (sNDA) was filed in July 2006[2] and which is currently pending.[3] The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova&#8482; will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM). 158747-02-5 77992 C14H17N3O 243.137160 White powder. Soluble Frovatriptan is rapidly absorbed from the duodenum, but has low oral bioavailability. Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT<sub>1D</sub> receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT<sub>1B/1D</sub> receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT<sub>1B</sub> receptor agonism. In vitro, cytochrome P450 1A2 appears to be the principal enzyme involved in the metabolism of frovatriptan to several metabolites including hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, and several other minor metabolites. Desmethyl frovatriptan has lower affinity for 5-HT<sub>1B/1D</sub> receptors compared to the parent compound. The N-acetyl desmethyl metabolite has no significant affinity for 5-HT receptors. The activity of the other metabolites is unknown. Route of Elimination: Radiolabeled compounds excreted in urine were unchanged frovatriptan, hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, together with several other minor metabolites. Less than 10% of frovatriptan was excreted in urine after an oral dose. Half Life: 26 hours No indication of carcinogenicity to humans (not listed by IARC). For the acute treatment of migraine attacks with or without aura in adults. There is no direct experience of any patient taking an overdose of Frovatriptan. The maximum single dose of frovatriptan given to male and female patients with migraine was 40 mg (16 times the clinical dose) and the maximum single dose given to healthy male subjects was 100 mg (40 times the clinical dose) without significant adverse events. As with other 5-HT1 receptor agonists, there is no specific antidote for frovatriptan. The elimination half-life of frovatriptan is 26 hours, therefore if overdose occurs, the patient should be monitored closely for at least 48 hours and be given any necessary symptomatic treatment. (L1712) 2009-07-21T20:28:08Z 2026-03-27T01:52:43Z Frovatriptan 350328 Frovatriptan DB00998 true CN[C@@H]1CCC2=C(C1)C1=C(N2)C=CC(=C1)C(N)=O C14H17N3O InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 XPSQPHWEGNHMSK-SECBINFHSA-N 243.3043 243.137162181 Exogenous Solid 0.9 HMDB15133 CHEMBL1279 70378 <p>Samir Naik, Anthony Crasto, Narendra Joshi, Sachin Srivastava, &#8220;Amorphous frovatriptan succinate and process for the preparation thereof.&#8221; U.S. Patent US20070299123, issued December 27, 2007.</p> CHEM002317 DTXSID0023080 NS00007851 (3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide